TP53 and neoplasm: Previous studies also demonstrated that the restoration of wild-type p53 function induced tumor regression in vivo through promoting apoptosis and/or senescence [20–22], suggesting that reactivating the p53 function in tumors retaining wild-type p53 is an attractive strategy for anticancer therapy.